Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Owen Jones, Marco Paw Claasen, Tommy Ivanics, Woo Jin Choi, Felipe Gavaria, Luckshi Rajendran, Anand Ghanekar, Gideon Hirschfield, Aliya Gulamhusein, Chaya Shwaartz, Trevor Reichman, Blayne Amir Sayed, Markus Selzner, Mamatha Bhat, Cynthia Tsien, Elmar Jaeckel, Les Lilly, Ian D McGilvray, Mark S Cattral, Nazia Selzner, Gonzalo Sapisochin
Background Living donor liver transplantation (LDLT) offers the opportunity to decrease waitlist time and mortality for patients with AILD; autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). We compared the survival of patients with a potential live donor (pLDLT) on the waitlist vs. no potential live donor (pDDLT), on an intention-to-treat (ITT) basis. Methods Our retrospective cohort study investigated adults with AILD listed for liver transplant at our program between 2000 and 2021...
April 16, 2024: Liver Transplantation
#2
JOURNAL ARTICLE
Palak J Trivedi, Katherine Arndtz, Nadir Abbas, Alison Telford, Liam Young, Rajarshi Banerjee, Peter Eddowes, Kartik S Jhaveri, Gideon M Hirschfield
BACKGROUND: Imaging markers of biliary disease in primary sclerosing cholangitis (PSC) have potential for use in clinical and trial disease monitoring. Herein, we evaluate how quantitative magnetic resonance cholangiopancreatography (MRCP) metrics change over time, as per the natural history of disease. METHODS: Individuals with PSC were prospectively scanned using non-contrast MRCP. Quantitative metrics were calculated using MRCP+ post-processing software to assess duct diameters and dilated and strictured regions...
April 3, 2024: Alimentary Pharmacology & Therapeutics
#3
JOURNAL ARTICLE
Christina G Plagiannakos, Gideon M Hirschfield, Ellina Lytvyak, Surain B Roberts, Marwa Ismail, Aliya F Gulamhusein, Nazia Selzner, Karim M Qumosani, Lawrence Worobetz, Julian Hercun, Catherine Vincent, Jennifer A Flemming, Mark G Swain, Angela Cheung, Tianyan Chen, Dusanka Grbic, Kevork Peltekain, Andrew L Mason, Aldo J Montano-Loza, Bettina E Hansen
BACKGROUND & AIMS: We sought to identify predictors of outcome for people living with autoimmune hepatitis (AIH). METHODS: We evaluated the clinical course of people with AIH across 11 Canadian centres. Biochemical changes were analysed using linear mixed-effect and logistic regression. Clinical outcome was dynamically modelled using time-varying Cox proportional hazard modelling and landmark analysis. RESULTS: In 691 patients (median age 49 years, 75...
March 23, 2024: Journal of Hepatology
#4
JOURNAL ARTICLE
David Ej Jones, Ulrich Beuers, Alan Bonder, Marco Carbone, Emma Culver, Jessica Dyson, Robert G Gish, Bettina E Hansen, Gideon Hirschfield, Rebecca Jones, Kris Kowdley, Andreas E Kremer, Keith Lindor, Marlyn Mayo, George Mells, James Neuberger, Martin Prince, Mark Swain, Atsushi Tanaka, Douglas Thorburn, Michael Trauner, Palak Trivedi, Martin Weltman, Andrew Yeoman, Cynthia Levy
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The management landscape was transformed 20 years ago with the advent of Ursodeoxycholic Acid (UDCA). Up to 40% of patients do not, however, respond adequately to UDCA and therefore still remain at risk of disease progression to cirrhosis. The introduction of Obeticholic acid (OCA) as second-line therapy for patients failing UDCA has improved outcomes for PBC patients. There remains, however, a need for better treatments for higher risk patients...
March 22, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#5
JOURNAL ARTICLE
Nasir Hussain, James Ferguson, Gideon M Hirschfield, Palak J Trivedi
No abstract text is available yet for this article.
February 29, 2024: Liver Transplantation
#6
RANDOMIZED CONTROLLED TRIAL
Gideon M Hirschfield, Christopher L Bowlus, Marlyn J Mayo, Andreas E Kremer, John M Vierling, Kris V Kowdley, Cynthia Levy, Alejandra Villamil, Alma L Ladrón de Guevara Cetina, Ewa Janczewska, Ehud Zigmond, Sook-Hyang Jeong, Yusuf Yilmaz, Yiannis Kallis, Christophe Corpechot, Peter Buggisch, Pietro Invernizzi, Maria Carlota Londoño Hurtado, Sandrin Bergheanu, Ke Yang, Yun-Jung Choi, Daria B Crittenden, Charles A McWherter
BACKGROUND: Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential benefits. METHODS: In this phase 3, 12-month, double-blind, placebo-controlled trial, we randomly assigned (in a 2:1 ratio) patients who had had an inadequate response to or who had a history of unacceptable side effects with ursodeoxycholic acid to receive oral seladelpar at a dose of 10 mg daily or placebo...
February 29, 2024: New England Journal of Medicine
#7
JOURNAL ARTICLE
Woo Jin Choi, Surain Roberts, Amol Verma, Fahad Razak, Grainne M O'Kane, Steven Gallinger, Gideon Hirschfield, Bettina Hansen, Gonzalo Sapisochin
BACKGROUND AND AIMS: The incidence of biliary tract cancers (BTC) appears to be increasing worldwide. We analyzed the characteristics of BTC-related hospitalizations under medical services across 28 hospitals in Ontario, Canada. METHODS: This study uses data collected by GEMINI, a hospital research data network. BTC-related hospitalizations from 2015 to 2021 under the Department of Medicine or intensive care unit were captured using the International Classification of Diseases, 10th revision, codes for intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma, and gallbladder cancers...
February 15, 2024: Cancer
#8
REVIEW
Palak J Trivedi, Gideon M Hirschfield, David H Adams, John M Vierling
Autoimmune liver diseases include primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis, a family of chronic immune-mediated disorders that target hepatocytes and cholangiocytes. Treatments remain nonspecific, variably effective, and noncurative, and the need for liver transplantation is disproportionate to their rarity. Development of effective therapies requires better knowledge of pathogenic mechanisms, including the roles of genetic risk, and how the environment and gut dysbiosis cause immune cell dysfunction and aberrant bile acid signaling...
February 10, 2024: Gastroenterology
#9
EDITORIAL
Gideon M Hirschfield, Ansgar W Lohse
No abstract text is available yet for this article.
February 1, 2024: Journal of Hepatology
#10
JOURNAL ARTICLE
Suz Warner, Jeremy Rajanayagam, Emily Russell, Carla Lloyd, James Ferguson, Deirdre A Kelly, Gideon M Hirschfield
BACKGROUND & AIMS: Long-term follow-up studies of paediatric onset autoimmune liver disease (AILD) are invaluable in helping better understand the clinical course of disease. In day-to-day practice clinicians struggle with disease definitions whilst patients and parents lack clear prognostic information. METHODS: The clinical progression of 159 patients with childhood onset AILD between June 1990 and December 2013 was reviewed, capturing data up to adulthood (ending May 2021)...
February 2024: JHEP reports: innovation in hepatology
#11
JOURNAL ARTICLE
Tallulah S Andrews, Diana Nakib, Catia T Perciani, Xue Zhong Ma, Lewis Liu, Erin Winter, Damra Camat, Sai W Chung, Patricia Lumanto, Justin Manuel, Shantel Mangroo, Bettina Hansen, Bal Arpinder, Cornelia Thoeni, Blayne Sayed, Jordan Feld, Adam Gehring, Aliya Gulamhusein, Gideon M Hirschfield, Amanda Ricciuto, Gary D Bader, Ian D McGilvray, Sonya MacParland
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an immune-mediated cholestatic liver disease for which there is an unmet need to understand the cellular composition of the affected liver and how it underlies disease pathogenesis. We aimed to generate a comprehensive atlas of the PSC liver using multi-omic modalities and protein-based functional validation. METHODS: We employed single-cell and single-nucleus RNA sequencing (47,156 cells and 23,000 nuclei) and spatial transcriptomics (one sample by 10x Visium and five samples with Nanostring GeoMx DSP) to profile the cellular ecosystem in 10 PSC livers...
January 8, 2024: Journal of Hepatology
#12
JOURNAL ARTICLE
Javaid Sadiq, Carla Lloyd, James Hodson, Maria Trapero Marugan, James Ferguson, Khalid Sharif, Darius F Mirza, Gideon Hirschfield, Deirdre Kelly
BACKGROUND: Biliary atresia (BA) is rare liver disease of unknown etiology, and is a major indication for liver transplant (LT). Previous data indicate improved outcomes with early referral for Kasai portoenterostomy (KPE). OBJECTIVE: Evaluate the long-term outcomes in BA, with particular focus on those transitioned to adult care with native livers. SUBJECTS AND METHODS: Patients with BA treated between1980 and 2012 were identified. Data were collected from the time of referral, transition to adult care, and the most recent clinic notes, from which patient and native liver survival were calculated...
December 2023: JGH Open: An Open Access Journal of Gastroenterology and Hepatology
#13
JOURNAL ARTICLE
Andreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, Cynthia Levy, Christopher L Bowlus, David E Jones, Jeff D Johnson, Charles A McWherter, Yun-Jung Choi
BACKGROUND AND AIMS: Pruritus is a debilitating symptom for many people living with primary biliary cholangitis (PBC). In studies with seladelpar, a selective PPAR-delta agonist, PBC patients experienced significant improvement in pruritus and reduction of serum bile acids. Interleukin-31 (IL-31) is a cytokine known to mediate pruritus and blocking IL-31 signaling provides relief in pruritic skin diseases. This study examined the connection between seladelpar's anti-pruritic effects, IL-31 and bile acid levels in PBC patients...
December 20, 2023: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#14
REVIEW
Inbal Houri, Gideon M Hirschfield
Primary biliary cholangitis (PBC) is the most common of the autoimmune liver diseases, in which there is chronic small bile duct inflammation. The pathophysiology of PBC is multifactorial, involving immune dysregulation and damage to biliary epithelial cells, with influences from genetic factors, epigenetics, the gut-liver axis, and environmental exposures.
February 2024: Clinics in Liver Disease
#15
JOURNAL ARTICLE
Marlyn J Mayo, John M Vierling, Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield, Guy W Neff, Michael R Galambos, Stuart C Gordon, Brian B Borg, Stephen A Harrison, Paul J Thuluvath, Aparna Goel, Mitchell L Shiffman, Mark G Swain, David E J Jones, Palak Trivedi, Andreas E Kremer, Richard J Aspinall, David A Sheridan, Yvonne Dörffel, Ke Yang, Yun-Jung Choi, Charles A McWherter
BACKGROUND: Seladelpar is a potent and selective peroxisome proliferator-activated receptor-δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti-cholestatic, anti-inflammatory and anti-pruritic effects. AIMS: To evaluate the long-term safety and efficacy of seladelpar in patients with PBC. METHODS: In an open-label, international, long-term extension study, patients with PBC completing seladelpar lead-in studies continued treatment...
October 30, 2023: Alimentary Pharmacology & Therapeutics
#16
JOURNAL ARTICLE
Woo Jin Choi, Richard Walker, Luckshi Rajendran, Owen Jones, Annie Gravely, Marina Englesakis, Steven Gallinger, Gideon Hirschfield, Bettina Hansen, Gonzalo Sapisochin
OBJECTIVE: To conduct a systematic review, critical appraisal, and external validation of survival prediction tools for patients undergoing intrahepatic cholangiocarcinoma (iCCA) resection. SUMMARY BACKGROUND DATA: Despite the development of several survival prediction tools in recent years for patients undergoing iCCA resections, there is a lack of critical appraisal and external validation of these models. METHODS: We conducted a systematic review and critical appraisal of survival and recurrence prediction models for patients undergoing curative-intent iCCA resections...
September 2023: Annals of surgery open: perspectives of surgical history, education, and clinical approaches
#17
JOURNAL ARTICLE
Fakhar Ali Qazi Arisar, Shiyi Chen, Catherine Chen, Noorulsaba Shaikh, Ravikiran Sindhuvalada Karnam, Wei Xu, Sumeet K Asrani, Zita Galvin, Gideon Hirschfield, Keyur Patel, Cynthia Tsien, Nazia Selzner, Mark Cattral, Leslie Lilly, Mamatha Bhat
Liver transplant (LT) candidates have become older and frailer, with growing Non-alcoholic steatohepatitis (NASH) and comorbid disease burden in recent years, predisposing them for poor waitlist outcomes. We aimed to evaluate the impact of access to living donor liver transplantation (LDLT) in waitlisted patients at highest risk of dropout. We reviewed all adult patients with decompensated cirrhosis listed for LT from November 2012 to December 2018. Patients with a potential living donor (pLD) available were identified...
September 2, 2023: Aging
#18
JOURNAL ARTICLE
Fernanda Onofrio, Katina Zheng, Cherry Xu, Shiyi Chen, Wei Xu, Mary Vyas, Katie Bingham, Keyur Patel, Leslie Lilly, Mark Cattral, Nazia Selzner, Elmar Jaeckel, Cynthia Tsien, Aliya Gulamhusein, Gideon M Hirschfield, Mamatha Bhat
BACKGROUND: Liver transplantation (LT) is frequently lifesaving for people living with primary sclerosing cholangitis (PSC). However, patients are waitlisted for LT according to the model for end-stage liver disease-sodium (MELD-Na) score, which may not accurately reflect the burden of living with PSC. We sought to describe and analyze the clinical trajectory for patients with PSC referred for LT, in a mixed deceased donor/living donor transplant program. METHODS: This was a retrospective cohort study from November 2012 to December 2019, including all patients with PSC referred for assessment at the University Health Network Liver Transplant Clinic...
August 1, 2023: Hepatology Communications
#19
JOURNAL ARTICLE
Christophe Corpechot, Sara Lemoinne, Pierre-Antoine Soret, Bettina Hansen, Gideon Hirschfield, Aliya Gulamhusein, Aldo J Montano-Loza, Ellina Lytvyak, Albert Pares, Ignasi Olivas, John E Eaton, Karim T Osman, Christoph Schramm, Marcial Sebode, Ansgar W Lohse, George Dalekos, Nikolaos Gatselis, Frederik Nevens, Nora Cazzagon, Alessandra Zago, Francesco Paolo Russo, Annarosa Floreani, Nadir Abbas, Palak Trivedi, Douglas Thorburn, Francesca Saffioti, Laszlo Barkai, Davide Roccarina, Vicenza Calvaruso, Anna Fichera, Adèle Delamarre, Natalia Sobenko, Alejandra Maria Villamil, Esli Medina-Morales, Alan Bonder, Vilas Patwardhan, Cristina Rigamonti, Marco Carbone, Pietro Invernizzi, Laura Cristoferi, Adriaan van der Meer, Rozanne de Veer, Ehud Zigmond, Eyal Yehezkel, Andreas E Kremer, Ansgar Deibel, Tony Bruns, Karsten Große, Aaron Wetten, Jessica Katharine Dyson, David Jones, Jérôme Dumortier, Georges-Philippe Pageaux, Victor de Lédinghen, Olivier Chazouillères, Fabrice Carrat
BACKGROUND AND AIMS: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (xULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains. APPROACH AND RESULTS: We performed a retrospective cohort study of 1,047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria...
July 3, 2023: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#20
RANDOMIZED CONTROLLED TRIAL
Gideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, Kris V Kowdley, John M Vierling, Cynthia Levy, Andreas E Kremer, Ehud Zigmond, Pietro Andreone, Stuart C Gordon, Christopher L Bowlus, Eric J Lawitz, Richard J Aspinall, Daniel S Pratt, Karina Raikhelson, Maria S Gonzalez-Huezo, Michael A Heneghan, Sook-Hyang Jeong, Alma L Ladrón de Guevara, Marlyn J Mayo, George N Dalekos, Joost P H Drenth, Ewa Janczewska, Barbara A Leggett, Frederik Nevens, Victor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak J Trivedi, Lisa Forman, David E J Jones, Stephen D Ryder, Mark G Swain, Alexandra Steinberg, Pol F Boudes, Yun-Jung Choi, Charles A McWherter
BACKGROUND AND AIMS: ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDCA). APPROACH AND RESULTS: Patients were randomized 1:1:1 to oral seladelpar 5 mg (n=89), 10 mg (n=89), placebo (n=87) daily (with UDCA, as appropriate)...
August 1, 2023: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
